Analysis of contemporary HIV/AIDS health care costs in Germany

Medicine (United States)

Volumn 95, Issue 26, 2016, Pages

  Treskova, Marina ^a   Kuhlmann, Alexander ^a   Bogner, Johannes ^b   Hower, Martin ^c   Heiken, Hans ^d   Stellbrink, Hans Jürgen ^e   Mahlich, Jörg ^f   Von Der Schulenburg, Johann Matthias Graf ^a   Stoll, Matthias ^g  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c KLINIKUM DORTMUND   (Germany)

^d Zentrum Innere Medizin   (Germany)

^e Infektionsmedizinisches Centrum Hamburg   (Germany)

^f JANSSEN CILAG GMBH   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

combination antiretroviral therapy; cost determinants; cost ratios; costs; HIV; prospective cohort survey; utilization

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CREATININE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE ANALOG; RALTEGRAVIR; RITONAVIR; ANTIRETROVIRUS AGENT;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNODEFICIENCY; CHOLESTEROL BLOOD LEVEL; COMBINATION DRUG THERAPY; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISABILITY; DISEASE SEVERITY; DRUG COST; EDUCATIONAL STATUS; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL TRIAL; ECONOMICS; HIV INFECTIONS; MULTICENTER STUDY; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; GERMANY; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84978661379     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003961     Document Type: Article

References (43)

1. Jaggy C, Overbeck F, Ledergerber B, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003;362:877-8
2. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013;8:e81355
3. Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015;29:221-9
4. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (November 13, 2014). Retrieved from http://aidsinfo.nih.gov/Content Files/Adultand
5. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2013
6. Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. J Am Med Associat 2014;312:410-25
7. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010;24:2705-15
8. Trapero-Bertran M, Oliva-Moreno J. Economic impact of HIV/AIDS: a systematic review in five European countries. Health Econ Rev 2014;4:15
9. Beck EJ, Harling G, Gerbase S, et al. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS 2010;5:215-24
10. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis 2006;6:171-7
11. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002;7:257-66
12. Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012;26:45-56
13. Gazzard B, Moecklinghoff C, Hill A. New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res 2012;4:193-200
14. Mostardt S, Hanhoff N, Wasem J, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econo 2013;14:799-808
15. Hoeper K, Stoll M, Schmidt RE, et al. Langzeitauswirkungen auf gesundheitsökonomische Folgekosten im Jahr 2010 durch den initialen antiretroviralen Therapiebeginn bei HIV-Patienten. Gesundheitswesen 2011;73
16. Kuhlmann A, Mittendorf T, Hower M, et al. Krankheitskosten von HIVPatienten unter antiretroviraler Therapie in Deutschland-Ergebnisse einer 48-Wochen-Interimsanalyse im Rahmen der prospektiven multizentrischen Kohortenstudie 'CORSAR'. Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany-Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'. Gesundheitswesen 2014
17. Mihaylova B, Briggs A,O'Hagan A, et al. Reviewof statistical methods for analysing healthcare resources and costs. Health Econ 2011;20:897-916
18. Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Services and Outcomes Research Methodology 2000;1:185-202
19. Braun S, Prenzler A, Mittendorf T, et al. Bewertung von Ressourcenverbräuchen im deutschen Gesundheitswesen aus Sicht der Gesetzlichen Krankenversicherung. Gesundheitswesen 2009;71:19-23
20. Prenzler A, Zeidler J, Braun S, et al. Bewertung von Ressourcen im Gesundheitswesen aus der Perspektive der deutschen Sozialversicherung. PharmacoEconomics German Research Articles 2010;8:47-66
21. Deutsches Statistisches Bundesamt. Krankenhausfälle, Krankenhaustage und Tage je Fall der Versicherten der gesetzlichen Krankenversicherung. Retrieved from http://www.gbe-bund.de
22. Deutsche Rentenversicherung Bund. Reha-Bericht 2012. Retrieved from http://www.deutsche-rentenversicherung.de/cae/servlet/contentblob/ 235592/publicationFile/30904/rehabericht-2012.pdf
23. Bundesministerium für Gesundheit. Ergebnisse der Statistik KG 5, Vorsorge-und Rehabilitationsmaßnahmen der Gesetzlichen Krankenversicherungen. Retrieved from http://www.bmg.bund.de/fileadmin/ dateien/Downloads/Statistiken/GKV/Geschaeftsergebnisse/ 120705-Ergebnisse-der-Statistik-KG-5-Vorsorge-und-Rehabilita tionsmassnahmen.pdf
24. Bundesarbeitsgemeinschaft für Rehabilitation. Statistik der Ausgaben für Rehabilitation und Teilhabe 2008-2010. Retrieved from http://www. bar-frankfurt.de/fileadmin/dateiliste/rehabilitation-und-teilhabe/Date nundFakten/downloads/Statistiktabelle-2008-2010.pdf
25. Kassenärztliche Bundesvereinigung. Kennzahlen der Abrechnungsgruppen 1. Quartal 2009 bis 1. Quartal 2012. Retrieved from https://www. kbv.de/41532.html
26. Claudia Kemper, Kristin Sauer, Gerd Glaeske. BARMER GEK Heil-und Hilfsmittel-Report 2011. Retrieved from https://presse.barmer-gek.de/ barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/Heil-und-Hilfsmittelreport/Einstieg-HeHi-Reports.html
27. Claudia Kemper, Kristin Sauer, Gerd Glaeske. BARMER GEK Heil-und Hilfsmittel-Report 2012. Retrieved from https://presse.barmer-gek.de/ barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/Heil-und-Hilfsmittelreport/Einstieg-HeHi-Reports.html
28. Kristin Sauer, Claudia Kemper, Kathrin Kaboth. BARMER GEK Heilund Hilfsmittel-Report 2010. Retrieved from https://presse.barmer-gek. de/barmer/web/Portale/Presseportal/Subportal/Infothek/Studien-und-Reports/Heil-und-Hilfsmittelreport/Einstieg-HeHi-Reports.htm
29. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89
30. Austin PC, Ghali WA, Tu JV. A comparison of several regression models for analysing cost of CABG surgery. Stat Med 2003;22:2799-815
31. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
32. Schackman B, Fleishman J, Su A, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care 2015;53:293-301
33. Leibowitz A, Desmond K. Identifying a sample of HIV-positive beneficiaries from medicaid claims data and estimating their treatment costs. Am J Public Health 2015;105:567-74
34. Stoll M, Kollan C, Bergmann F, et al. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. PLoS One 2011;6:e23946
35. Krentz HB, Gill MJ. The Direct Medical Costs of Late Presentation. AIDS Res Treat 2012;1-8
36. Miro JM, Manzardo C, Mussini C, et al. Survival outcomes and effect of early vs. Deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. PLoS One 2011;6: e26009
37. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Safety 2005;28:1075-83
38. Hellinger FJ, Fleishman JA. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J Acquir Immune Defic Syndr 2000;24:182-8
39. Raveis VH, Siegel K, Gorey E. Factors associated with HIV-infected women's delay in seeking medical care. AIDS Care 1998;10:549-62
40. Ruof J, Schwartz FW, Schulenburg JM, et al. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation. Eur J Health Econ 2014;15:577-89
41. García Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10
42. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med 2000;133:21-30
43. Gardner EM, Burman WJ, Steiner JF, et al. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 2009;23:1035-46